Drug guidance
Botulinum toxin type A for the prophylaxis of headaches in adults with chronic migraine
Condition
Neurology
4 January 2022
Published on 04 Jan 2022
Last Updated on 04 Jan 2022
Guidance Recommendations
The Ministry of Health's Drug Advisory Committee has recommended:
Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 U and 100 U injection vials for the prophylaxis of headaches in adults with chronic migraine who have had an inadequate response, intolerance, or contraindication to at least three migraine prophylactic medications.
Botulinum toxin type A must be administered by a neurologist.
Subsidy status
Clostridium botulinum toxin type A neurotoxin complex (Botox) 50 U and 100 U injection vials are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication.
MAF assistance does not apply to Botox 200 U injection vial, Dysport 300 U and 500 U injection vials, and Xeomin 50 U and 100 U injection vials.